Toggle Dropdown
Announcements
Projects
News & Events
Welcome guest
Log in
Loading
Loading...
https://www.targetedonc.com/view/adding-bevacizumab-to-trifluridine-tipiracil-boosts-survival-disease-control-rate-in-mcrc
0
0
Adding Bevacizumab to Trifluridine/Tipiracil Boosts Survival, Disease Control Rate in mCRC - Targeted Oncology
1/22/23 at 3:34am
Organization
Targetedonc.com
Authors
Tony Berberabe
MPH
48 words
0
Comments
The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.
Cancer
Business & Industrial
Bevacizumab
Tipiracil Boosts Survival
Trifluridine
mCRC
Oncology The SUNLIGHT
Josep Tabernero
You are the first to view
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...